No Detail Found!

Stem Cell Mobilisation Failure in Auto HSCT and Its Factors: A Single Centre Experience

Author(s)
Irsa Hidayat Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Mehreen Ali Khan Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Munazza Nabi Awan Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Awais Siddiq Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Sahla Riaz Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Qudrat Ullah Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Abstract
Objective: To determine the mobilisation failure rate and identify its associated factors in this part of the world in order to identify patients at risk of mobilisation failure and to promptly explore alternative treatment. Study Design: A descriptive study. Place and Duration of the Study:Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan, from January 2014 to July 2023. Methodology: Clinical records of 115 patients due for autologous haematopoietic stem cell transplantation (auto HSCT) and undergoing mobilisation regimen were analysed. Poor mobilisers were de ned as patients who failed to achieve minimum PBSC collection of CD34 >2 x 106/kg of recipient body-weight or required an additional dose of Plerixafor after Cyclophosphamide GCSF mobilisation to achieve the target dose. Results: Among the mobilisation regimes, 85 (74%) were mobilised with Cyclophosphamide followed by GCSF (Cyclo-G), 28 (24%) with GCSF and Plerixafor (G-Plerixafor), and only 2 (2%) with GCSF alone.After the rst mobilisation regimen, 84% of patients achieved PBSC collection of CD34 count of >2 x 10^6/kg. The entire mobilisation failure rate was 16%.Successful stem cell collection was signi cantly correlated with age, lymphoma group and its transplant indication, previous chemotherapy lines, exposure to the type of myelotoxic medicines, steady-state CD34 count, and use of Plerixafor. However, at multivariate analysis, only use of Plerixafor was found associated with successful mobilisation. Conclusion: Plerixafor signi cantlyimproved mobilisation regimens' yield and cost-e ectiveness by greatly increasing mobilisation success rates, particularly in heavily pre-treated lymphoma patients.
Publication Details
Page(s) 367-371
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Lymphoma, Multiple myeloma, Plerixafor, Haematopoietic stem cell mobilisation, Plasma cell dyscrasias
References
Johnsrud A,Ladha A,Mu L,Shiraz P,Goldstein G,Osgood V .2021 .Stem cell mobilisation in multiple myeloma: Comparing safety and e cacy of cyclophosphamide +/- plerixafor versus granulocyte colonystimulating factor +/- plerixafor in the lenalidomide era. Transplant Cell Ther, 04(7) : 590-8.
Luo C,Wu G,Huang X,Zhang Y,Ma Y,Huang Y .2022 .E cacy of hematopoietic stem cell mobilisation regimens in patients with hematological malignancies: A systematic review and network meta-analysis of randomised controlled trials. Stem Cell Res Ther, 10(1) : 123.
Chandler T,Parrish C,Karakantza M,Carmichael J,Pawson D,Cook G .2023 .A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilisation matters in the era of IMiD induction. EJHaem, 10(3) : 702-30.
Chen J,Lazarus HM,Dahi PB,Avecilla S,Giralt SA .2020 .Getting blood out of a stone: Identi cation and management of patients with poor hematopoietic cell mobilisation. Blood Rev, 100771 : 100771.
Demiroglu H,Ciftciler R,Buyukasik Y,Goker H Y .2020 .Prediction of stem cell mobilisation failure in patients with hodgkin and non-hodgkin lymphoma. Turk J Haematol, 0409(3) : 204-10.
Namdaroglu S,Korkmaz S .2017 .Management of mobilisation failure in 2017. Transfus Apher Sci, 11(6) : 836-44.
Bakeer M,Zubair AC,Roy V .2019 .Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilisation. Cytotherapy, 10(1) : 16-20.
Rozario D,Parisotto J,Stapleton R,Gidley J,Owen A,D A .2014 .Pre-infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of hematopoietic engraftment in autologous haematopoietic cell transplantation. Transfus Apher Sci, 02(3) : 443-50.
Zheng G,He J,Cai Z,He D,Luo Y,Shi J .2019 .A retrospective study of autologous stem cell mobilisation by G CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma. Oncol Lett, 11177(1) : 1051-9.
Bonora BM,Cappellari R,Mazzucato M,Rigato M,Grasso M,Menegolo M .2020 .Stem cell mobilisation with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomised, double-blind, placebo-controlled trial. Stem Cells Transl Med, 10(9) : 0020-73.
Carreras E,Dufour C,Mohty M,Kroger N. .2019 .The EBMT handbook: Hematopoietic stem cell transplantation and cellular therapies. , : .
Chen KY,Bucci TG,Shaw JR,Alexander MD,Grgic T,Riches M .2021 .Plerixafor strategies for autologous haematopoietic cell transplant mobilisation: A comparison of e cacy and cost. Transfus Apher Sci, 103303(2) : 103303.
Sadri S,Hindilerden IY,Mutlu YG,Tiryaki TO,Gemici AI,Bekoz HS .2023 .Comparison of di erent plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilisers. Eur Res J, 10(6) : 1-2.
Krishnamurthy KP,Sarathy V,Jayappa SB,Badarkhe GV,Ks RK,Thianeshwaran S .2021 .Study of peripheral mononuclear cells and CD34 levels as a predictive marker for initiating apheresis in autologous stem cell transplant. Int J Hematol Oncol Stem Cell Res, 10(3) : 6847-7.
Kriegsmann K,Bittrich M,Sauer S,Stolley CT,Movassaghi K,Grube M .2023 .Mobilisation and hematopoietic stem cell collection in poor mobilizing patients with lymphoma: Final results of the German OPTIMOB study. Transfus Med Hemother, 10(5) : 403-16.
Furlong E,Jensen J,Woodard M,Gri ths K,Knight G,Sturm M .2020 .Optimized peripheral blood progenitor cell Mobilisation for autologous hematopoietic cell transplantation in children with highrisk and refractory malignancies. Pediatr Transpl, 10(1) : .
Sauer S,Erdmann K,Jensen AD,Wennmann M,Pavel P,Jordan K .2021 .Local radiation therapy before and during induction delays stem cell mobilisation and collection in multiple myeloma patients. Transpl Cell Ther, 06(10) : 876-1.
Hsu TL,Tsai CK,Liu CY,Yeh CM,Lin FL,Hsiao LT .2023 .Risk factors and outcomes of stem cell mobilisation failure in multiple myeloma patients. Transfus Med Hemother, 10(1) : 39-50.
Weeks CJ,Bradshaw D,Mian MA,Shah A,Kim KJ,Abbagoni S .2023 .Elevated ferritin prior to collection and mobilisation may predict low stem cell yield. Transpl Cell Ther, 12(2) : S155-6.
0

Citations

0

Downloads

57

Views